Eisai’s Cancer Strategy Bears Early IO Combo Fruit
Interim data from a Phase Ib/II of a combination of Eisai’s halichondrin Halaven with Merck & Co’s immuno-oncology product Keytruda suggest it could represent a novel treatment regimen in patients with metastatic triple negative breast cancer, in an early vindication for the Japanese company’s strategy of expanding its oncology franchise.
You may also be interested in...
Eisai's lenvatinib has hit its primary endpoint in a large Phase III trial comparing it with sorafenib in first-line hepatocellular carcinoma, paving the way for regulatory filings in the important indication and strengthening the firm's expansion strategy in oncology.
Merck & Co and Eisai have signed a deal to assess various combinations of their immuno-oncology drugs in clinical trials. Merck's anti-PD-1 therapy, pembrolizumab (Keytruda) is to be tested in combination with Eisai's lenvatinib (Lenvima) and eribulin (Halaven) in multiple clinical studies.